Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2025 08:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for...
June 20, 2025 08:13 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Addition to Russell 3000® Index

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the...
June 05, 2025 07:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025...
May 14, 2025 07:32 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor...
May 07, 2025 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports First Quarter 2025 Financial Results

First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin...
May 01, 2025 17:07 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the...
April 22, 2025 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial...
March 31, 2025 08:00 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Stock Repurchase Program

GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the...
March 20, 2025 16:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across...
March 20, 2025 08:06 ET | Source: Emergent BioSolutions

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO®...